SYBX Stock Overview
A biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Synlogic, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.08 |
| 52 Week High | US$1.88 |
| 52 Week Low | US$0.90 |
| Beta | 0.56 |
| 1 Month Change | 1.89% |
| 3 Month Change | -21.17% |
| 1 Year Change | -33.33% |
| 3 Year Change | -94.05% |
| 5 Year Change | -96.90% |
| Change since IPO | -99.40% |
Recent News & Updates
Recent updates
Companies Like Synlogic (NASDAQ:SYBX) Could Be Quite Risky
Dec 28
Can Synlogic (NASDAQ:SYBX) Afford To Invest In Growth?
Sep 12We're A Little Worried About Synlogic's (NASDAQ:SYBX) Cash Burn Rate
May 01Here's Why We're Watching Synlogic's (NASDAQ:SYBX) Cash Burn Situation
Nov 23Synlogic Therapeutics: SYNB1934 Advances To Phase 3
Oct 20Synlogic gets milestone payment under Roche pact to discover synthetic biotic for bowel disease
Sep 06Synlogic's metabolic disorder drug gets FDA fast track status
Aug 23Synlogic Q2 2022 Earnings Preview
Aug 10Is Synlogic (NASDAQ:SYBX) In A Good Position To Invest In Growth?
Aug 09Synlogic begins dosing in early-stage trial of SYNB1353 for rare metabolic disorder
Jul 12Here's Why We're Watching Synlogic's (NASDAQ:SYBX) Cash Burn Situation
Jan 11Companies Like Synlogic (NASDAQ:SYBX) Are In A Position To Invest In Growth
Sep 28Here's Why We Think Synlogic, Inc.'s (NASDAQ:SYBX) CEO Compensation Looks Fair
Jun 03Companies Like Synlogic (NASDAQ:SYBX) Are In A Position To Invest In Growth
Feb 23Synlogic (NASDAQ:SYBX) Share Prices Have Dropped 67% In The Last Three Years
Jan 19Our Take On Synlogic's (NASDAQ:SYBX) CEO Salary
Dec 15
Shareholder Returns
| SYBX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.0% | 1.4% | 2.9% |
| 1Y | -33.3% | -14.7% | 11.9% |
Return vs Industry: SYBX underperformed the US Biotechs industry which returned -14.7% over the past year.
Return vs Market: SYBX underperformed the US Market which returned 11.9% over the past year.
Price Volatility
| SYBX volatility | |
|---|---|
| SYBX Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 12.0% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: SYBX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SYBX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 1 | Mary Dooley | www.synlogictx.com |
Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts.
Synlogic, Inc. Fundamentals Summary
| SYBX fundamental statistics | |
|---|---|
| Market cap | US$12.63m |
| Earnings (TTM) | US$2.56m |
| Revenue (TTM) | n/a |
4.9x
P/E Ratio0.0x
P/S RatioIs SYBX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SYBX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | -US$2.56m |
| Earnings | US$2.56m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.22 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SYBX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 16:52 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Synlogic, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christopher Howerton | Jefferies LLC |
| Joseph Schwartz | Leerink Partners LLC |
| Mark Breidenbach | Oppenheimer & Co. Inc. |